We currently do not have sufficient information about the CEO.
Key information
Shlomo Pilo
Chief executive officer
US$240.0k
Total compensation
CEO salary percentage
100.00%
CEO tenure
5.2yrs
CEO ownership
19.7%
Management average tenure
4.8yrs
Board average tenure
no data
Recent management updates
Recent updates
CEO Compensation Analysis
How has Shlomo Pilo's remuneration changed compared to Raphael Pharmaceutical's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
-US$1m
Dec 31 2025
US$240k
US$240k
-US$1m
Sep 30 2025
n/a
n/a
-US$1m
Jun 30 2025
n/a
n/a
-US$1m
Mar 31 2025
n/a
n/a
-US$1m
Dec 31 2024
US$240k
US$240k
-US$2m
Sep 30 2024
n/a
n/a
-US$1m
Jun 30 2024
n/a
n/a
-US$1m
Mar 31 2024
n/a
n/a
-US$2m
Dec 31 2023
US$244k
US$244k
-US$1m
Sep 30 2023
n/a
n/a
-US$3m
Jun 30 2023
n/a
n/a
-US$3m
Mar 31 2023
n/a
n/a
-US$3m
Dec 31 2022
US$370k
US$120k
-US$3m
Sep 30 2022
n/a
n/a
-US$3m
Jun 30 2022
n/a
n/a
-US$2m
Mar 31 2022
n/a
n/a
-US$2m
Dec 31 2021
US$120k
US$120k
-US$2m
Sep 30 2021
n/a
n/a
-US$1m
Jun 30 2021
n/a
n/a
-US$1m
Mar 31 2021
n/a
n/a
-US$850k
Dec 31 2020
US$110k
US$110k
-US$718k
Compensation vs Market: Shlomo's total compensation ($USD240.00K) is below average for companies of similar size in the US market ($USD655.15K).
Compensation vs Earnings: Shlomo's compensation has been consistent with company performance over the past year.
CEO
Shlomo Pilo (71 yo)
5.2yrs
Tenure
US$240,000
Compensation
Mr. Shlomo Pilo has been Chief Executive Officer and Director of Raphael Pharmaceutical Inc. since May 14, 2021 and had been its Chairman of the Board until January 8, 2025 and previously served in such ca...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Shlomo Pilo
CEO & Director
5.2yrs
US$240.00k
19.74% $ 5.6m
Igal Hayon
Chief Technology Officer
4.8yrs
US$288.00k
6.69% $ 1.9m
Uri Tadelis
Chief Financial Officer
no data
no data
no data
4.8yrs
Average Tenure
Experienced Management: RAPH's management team is considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/23 21:03
End of Day Share Price
2026/04/29 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Raphael Pharmaceutical Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.